IL2 and breast cancer: We also conducted a phase I trial in 10 advanced metastatic breast cancer patients, using the same Zoledronate and IL-2 regimen as in the above study (60), and found that 3 patients who sustained Vγ9Vδ2 T cell numbers achieved either disease stabilization (2 patients) or partial remission (1 patient).